findmyKOL

Roxana Mehran, MD

Enriched profile

Mount Sinai Professor in Cardiovascular Clinical Research and Outcomes; Director of Interventional Cardiovascular Research and Clinical Trials, Zena and Michael A. Weiner Cardiovascular Institute · Icahn School of Medicine at Mount Sinai

ORCIDNone on fileNPI↗
✓ Full profile
Region🇺🇸 New York, NY · Northeast · United StatesSpecialtyCardiovascular DiseaseFocusCoronary Artery Disease / ACS+11
Active KOLEmergingfindmyKOL type: EliteLatest publication2025Online presenceNone verifiedPayments2021–2025NIH funding2026–2026Why? →

Roxana Mehran is Mount Sinai Professor in Cardiovascular Clinical Research and Outcomes; Director of Interventional Cardiovascular Research and Clinical Trials, Zena and Michael A. Weiner Cardiovascular Institute at Icahn School of Medicine at Mount Sinai. ClinicalTrials.gov lists 24 registered studies with this person as an investigator.

Data verified 11 Oct 2026

Overview

Updated 13 Oct 2026

Roxana Mehran, M.D., is Mount Sinai Professor in Cardiovascular Clinical Research and Outcomes at Icahn School of Medicine at Mount Sinai. The public record shows 23 publications with 362 citations (h-index 8), centered on Coronary Artery Disease / ACS, Coronary Artery Disease, Aortic Valve Stenosis. It also documents an investigator role on 24 registered clinical trials, industry payments reported by 28 companies, 1 NIH-funded awards (2026–2026).

  • Top research focus: Coronary Artery Disease / ACS
  • 24 registered trials on ClinicalTrials.gov
  • Open Payments reporting from 28 companies

Generated from the cited public record · current as of 13 Oct 2026. Every fact links its source below.

Indications focus

from trials led + research topics
Coronary Artery Disease / ACS10 trialsCoronary Artery Disease8 trialsAortic Valve Stenosis3 trialsConstriction, Pathologic3 trialsMyocardial Infarction2 trialsInfarction2 trialsThrombosis1 trialAtherosclerosis1 trialAtrial Fibrillation1 trialStroke1 trialChronic Kidney Disease1 trialHemorrhage1 trialRenal Insufficiency1 trialHematologic Diseases1 trialThrombocytopenia1 trialHemorrhagic Stroke1 trialCytopenia1 trialHeart Arrest1 trialDeath, Sudden, Cardiac1 trialHypertension1 trialHypertension Resistant to Conventional Therapy1 trialIschemia1 trialReperfusion Injury1 trialAcute Coronary Syndrome1 trial

Research focus

OpenAlex concept fingerprint
Coronary Artery Disease / ACSCoronary Artery DiseaseAortic Valve StenosisInfarctionMyocardial InfarctionAcute Coronary SyndromeDeath, Sudden, CardiacHeart ArrestHypertensionHypertension Resistant to Conventional TherapyIschemiaReperfusion Injury

Drugs & molecules

across trials, industry payments and publications
Leqviogeneric · InclisiranClinical trials—Industry payments15Publications—Repathageneric · EvolocumabClinical trials—Industry payments6Publications—SelatogrelClinical trials—Industry payments6Publications—Entrestogeneric · Sacubitril / valsartanClinical trials—Industry payments1Publications—Ozempicgeneric · SemaglutideClinical trials—Industry payments1Publications—

Works with

trial sponsors and companies reporting payments
Boston Scientific CorporationClinical trials1Industry payments2Medtronic, Inc.Clinical trials—Industry payments55Novo Nordisk ASClinical trials—Industry payments35Janssen Research & Development, LLCClinical trials—Industry payments23Novartis Pharmaceuticals CorporationClinical trials—Industry payments22Edwards Lifesciences CorporationClinical trials—Industry payments12Abbott LaboratoriesClinical trials—Industry payments9Idorsia Pharmaceuticals Us IncClinical trials—Industry payments8CSL BehringClinical trials—Industry payments7Amgen Inc.Clinical trials—Industry payments6Cordis Us Corp.Clinical trials—Industry payments6Icahn School of Medicine at Mount SinaiClinical trials6Industry payments—Bayer Healthcare Pharmaceuticals Inc.Clinical trials—Industry payments5Penumbra, Inc.Clinical trials—Industry payments5Sanofi Us Services Inc.Clinical trials—Industry payments4Abbott Medical DevicesClinical trials3Industry payments—Daiichi Sankyo Company LTDClinical trials—Industry payments3Daiichi Sankyo Inc.Clinical trials—Industry payments3E.R. Squibb & Sons, L.L.C.Clinical trials—Industry payments3Boehringer Ingelheim International GmbHClinical trials—Industry payments2Chiesi USA, Inc.Clinical trials—Industry payments2Novo Nordisk IncClinical trials—Industry payments2Philips Electronics North America CorporationClinical trials—Industry payments2Recor Medical IncClinical trials—Industry payments2AUM Cardiovascular, Inc.Clinical trials1Industry payments—Biotronik Inc.Clinical trials—Industry payments1CardioRenal Systems, Inc.Clinical trials1Industry payments—Cardiovascular Research Foundation, New YorkClinical trials1Industry payments—CellAegis US, Inc.Clinical trials1Industry payments—Ceric SàrlClinical trials1Industry payments—

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
8h-index

Hirsch index, productivity × impact (OpenAlex).

Clinical & industry

trials, payments and federal funding
24clinical trials

Investigator role on registered studies.

View trials ↓
28companies · 2021–2025

Companies reporting payments to CMS. Facts, not judgments.

View payments ↓
1NIH grants · 2026–2026

Federally funded research awards.

View funding ↓

Public positions

sourced statements on record

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

Telephone

Practice address and telephone from the federal NPPES registry.

Sign in to view contact details →

Clinical trials

Updated 13 Oct 2026

Listed as an investigator on 24 registered studies on ClinicalTrials.gov. The most recent:

Industry payments

Updated 13 Oct 2026

28 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Cardiovascular

    92.3%
    Statin54.2%
    Rosuvastatin Calcium85%Atorvastatin Calcium16%
    Part D<11 patients
    Angiotensin receptor blocker (ARB)23.2%
    Losartan Potassium100%
    Part D≥12 patients

    + 2 more classes in this area

  • Nervous system

    7.7%
    Other nervous system drugs7.7%
    Vyndamax100%
    Part D<11 patients
Where care is delivered (Part B)0% facility · 100% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

Updated 13 Oct 2026

1 NIH research award on record, funded 2026–2026 per NIH RePORTER. The latest:

Publications

Matched to this physician's OpenAlex author record; most-cited works shown first.

Background & recognition

Updated 13 Oct 2026

Credentials, appointments and honors, newest first, each linked to the public source it came from.

Education

degrees and training on record
  • verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →scai.org ↗

Editorial & leadership roles

journal and society appointments

Awards & honors

honors on the public record

Secondary affiliations

appointments beyond the home institution

Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.

Similar KOLs

Other experts from the same institution or the same specialty.